Roche licences antiviral nucleoside from Atea
Roche AG has paid US$350 in cash to co.develop and market Atea Pharmaceuticals oral direct-acting antiviral, AT-527, to limit proliferation of SARS-CoV-2.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1191 entries already.
Entries by Thomas Gabrielczyk
ADC company Araris Biotech raises CHF15.2m
/in News/by Thomas GabrielczykNew ADC company Araris Biotech has got backing by Pureos Bioventures and co-investors in a CHF15.2m seed round to develop a new class of antibody drug conjugates. ·
Vifor Pharma in US$100m licence deal with Cara Therapeutics
/in News/by Thomas GabrielczykVifor Pharma and Cara Therapeutics have signed a US license agreement for Korsuva to treat dialysis patients with pruritus.
Atriva Therapeutics gets 24m from EIB
/in News/by Thomas GabrielczykAtriva Therapeutics has secured a 24m loan to push the development of its COVID-19 programme ATR-002, an antiviral, anti-inflammatory MEK inhibitor.
Topas raises 22m in Series B financining
/in News/by Thomas GabrielczykTopas Therapeutics GmbH will use the 22m proceeds from a Series B Financing to advance two pipeline candidates.
Siemens launches COVID-19 antigen lateral flow test
/in News/by Thomas GabrielczykSiemens Healthineers has launched its Clinitest Rapid COVID-19 Antigen Test in Europe, which can identify persons infected with SARS-CoV-2 in 15 minutes.
Priothera closes 30m Series A financing
/in News/by Thomas GabrielczykPriothera Ltd. wants to use 30m from a Series A financing to develop a licenced therapy for acute myeloid leukemia (AML).
COVID-19 jab: EU signs contract with JNJ
/in News/by Thomas GabrielczykJohnson & Johnson (JNJ) has inked a contract with the European Commission to supply 200 million doses of its COVID-19 vaccine to the European Union.
Santhera ends development of idebenone
/in News/by Thomas GabrielczykSwiss Santhera Pharmaceuticals has discontinued Phase III development of its DMD drug and will restructure its pipeline.
Nobel Prize in Physiology for HCV pioneers
/in News/by Thomas GabrielczykThe Nobel Prize in Physiology or Medicine goes to Harvey J. Alter, Michael Houghton and Charles M. Ric